Form 4: KalVista Pharma CEO Completes Stock Transactions Amid Merger

KalVista Pharmaceuticals CEO Benjamin L. Palleiko reported transactions involving stock options and restricted stock units on June 11, 2026, related to the company's merger with Chiesi Farmaceutici S.p.A.

Summary

• Benjamin L. Palleiko, CEO of KalVista Pharmaceuticals, Inc., reported a series of transactions on June 11, 2026, related to stock options and restricted stock units (RSUs).
• These transactions occurred in connection with the Agreement and Plan of Merger dated April 29, 2026, between KalVista Pharmaceuticals, Chiesi Farmaceutici S.p.A., and Skyline Merger Sub, Inc.
• The merger involved a cash tender offer by Merger Sub to acquire all outstanding shares of KalVista common stock for $27.00 per share.
• As of June 11, 2026, Palleiko held 479,989 shares of common stock directly.
• Various stock options, with exercise prices ranging from $6.74 to $25.95, were vested, cancelled, and converted into the right to receive a cash payment based on the merger consideration ($27.00) minus the exercise price.
• Restricted Stock Units (RSUs) were also vested, cancelled, and converted into the right to receive a cash payment of $27.00 per share.
• Specific details on the number of shares subject to each option and RSU are provided, indicating a significant portion of Palleiko's equity holdings were affected by the merger.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for the reporting person, as the merger provides a clear cash realization event for their equity holdings at a defined premium.

Positives

• The merger agreement provides a clear cash payout of $27.00 per share for common stock, stock options, and RSUs, offering immediate value realization for shareholders and option/RSU holders.
• All outstanding stock options with an exercise price below the merger consideration were fully vested and converted into cash, maximizing the benefit for the CEO.
• All outstanding RSUs were fully vested and converted into cash, ensuring the CEO benefits from these awards.

Negatives

• Stock options with an exercise price equal to or greater than the merger consideration of $27.00 were cancelled for no consideration, representing a loss for any such hypothetical holdings.
• The filing details the disposition of equity awards due to the merger, indicating the end of KalVista Pharmaceuticals as an independent publicly traded entity.

Risks

• The primary risk mentioned is the cancellation of stock options with an exercise price at or above the merger consideration ($27.00), resulting in no payout for those specific awards.
• The merger itself represents a significant change, and while the cash payout is defined, the future of the business under new ownership introduces strategic uncertainties for stakeholders not directly involved in the transaction terms.

Future Outlook

The filing pertains to a completed merger, indicating the future operations and equity of KalVista Pharmaceuticals will be under the ownership of Chiesi Farmaceutici S.p.A. Specific forward-looking statements regarding the combined entity's performance are not detailed in this Form 4.

Management Comments

• The transactions are explained as being pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026.
• The merger involved a cash tender offer for all issued and outstanding shares of common stock at $27.00 per share.
• Stock options and RSUs were vested, cancelled, and converted into the right to receive a cash payment based on the merger consideration, less exercise price for options.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a common outcome in the biopharmaceutical sector where successful development or strategic assets attract acquisition offers, leading to the conversion of equity awards into cash payouts for executives and shareholders.

Legal Proceedings

• The filing references the Agreement and Plan of Merger, which is a legal document governing the transaction.

Stakeholder Impact

• Shareholders: Will receive $27.00 per share in cash for their common stock.
• Option Holders (including CEO): Will receive cash payments for vested options, calculated as the merger consideration minus the exercise price.
• RSU Holders (including CEO): Will receive cash payments for vested RSUs, equal to the merger consideration per share.
• Employees: May be impacted by changes in employment terms or roles under the new ownership structure, though specific details are not in this filing.
• Creditors: The merger terms do not suggest an immediate negative impact on creditors, as the transaction is a cash acquisition.

Next Steps

• The merger has been completed, with KalVista Pharmaceuticals becoming a wholly owned subsidiary of Chiesi Farmaceutici S.p.A.
• Holders of vested stock options and RSUs will receive cash payments as per the merger agreement.

Key Dates

Recommendation

This Form 4 filing details the completion of a merger and the resulting cash payout for executive equity. For existing shareholders, the transaction represents a realization event. For potential investors, the company will no longer be independently traded, making a traditional 'buy' recommendation inapplicable. A 'hold' is appropriate for existing shareholders who have received or will receive the cash payout, as there is no further stock to trade.

Keywords

Form 4, SEC Filing, KalVista Pharmaceuticals, Benjamin L. Palleiko, Merger, Chiesi Farmaceutici, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading, Executive Compensation